Form 8-K - Current report:
SEC Accession No. 0001628280-25-013681
Filing Date
2025-03-19
Accepted
2025-03-19 08:32:16
Documents
20
Period of Report
2025-03-17
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K cdxc-20250317.htm   iXBRL 8-K 28109
2 EX-3.1 niagenbioscienceinc-deam.htm EX-3.1 1700
3 EX-3.2 ex32-niagenbioscienceincam.htm EX-3.2 130375
4 EX-99.1 ex991-niagenbiosciencebran.htm EX-99.1 21793
8 image_0a.jpg GRAPHIC 67251
9 image_1a.jpg GRAPHIC 471827
10 niagenbioscienceinc-deam001.jpg GRAPHIC 91632
11 niagenbioscienceinc-deam002.jpg GRAPHIC 125113
  Complete submission text file 0001628280-25-013681.txt   1387911

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT cdxc-20250317.xsd EX-101.SCH 1776
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT cdxc-20250317_lab.xml EX-101.LAB 22592
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT cdxc-20250317_pre.xml EX-101.PRE 13054
22 EXTRACTED XBRL INSTANCE DOCUMENT cdxc-20250317_htm.xml XML 2835
Mailing Address 10900 WILSHIRE BLVD SUITE 600 LOS ANGELES CA 90024
Business Address 10900 WILSHIRE BLVD SUITE 600 LOS ANGELES CA 90024 310-388-6706
Niagen Bioscience, Inc. (Filer) CIK: 0001386570 (see all company filings)

EIN.: 262940963 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37752 | Film No.: 25750940
SIC: 2833 Medicinal Chemicals & Botanical Products
(CF Office: 03 Life Sciences)